The mechanism of NTNG1 promotes cisplatin resistance in ovarian cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041078

Enrollment

Unknown

Registered

2020-12-17

Start date

2020-12-05

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

cisplatin rensitance:Nil

cisplatin sensitive:Nil

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ovarian cancer cisplatin-based chemotherapy after debulking surgery.

Exclusion criteria

Exclusion criteria: chemotherapy before debulking surgery.

Design outcomes

Primary

Measure	Time frame
NTNG1;	—

Countries

China

Contacts

Public ContactTinghe Yu

The Second Affiliated Hospital, Chongqing Medical University

yutinghe@cqmu.edu.cn+86 13370735483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026